Printer Friendly

Zogenix, Inc. Names Founding Management Team.

SAN DIEGO & HAYWARD, Calif. -- Zogenix, Inc. is a privately held specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. In conjunction with today's separate announcement of the company's $60 million Series A financing, Zogenix named its founding management team. The founding members are:

--Cam L. Garner, Chairman of the Board of Directors;

--Roger L. Hawley, Chief Executive Officer;

--Stephen J. Farr, Ph.D., President and Chief Operating Officer;

--Jonathan Rigby, Vice President of Business Development;

--Bret E. Megargel, Vice President of Finance and Corporate Development; and

--John J. Turanin, Vice President of Operations.

Cam L. Garner, a founder and Chairman, has more than 30 years relevant industry experience, including leading the formation and successful growth of Dura Pharmaceuticals, Inc., which was acquired by Elan Corporation, plc in 2000 for $1.8 billion. He has recently formed specialty pharmaceutical companies Verus Pharmaceuticals, Inc. and Cadence Pharmaceuticals, Inc. Mr. Garner serves as Chairman and CEO of Verus and Chairman of Cadence. In 1998, Mr. Garner founded and served as Chairman of DJ Pharma, which was sold to Biovail in 2000. In 2001, he founded and served as Chairman of Xcel Pharmaceuticals, which was sold to Valeant in 2005. Currently, he is Chairman of Favrille, Inc. (NASDAQ:FVRL) and serves on the board of numerous companies, including Pharmion Corporation (NASDAQ:PHRM), Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), SkinMedica, Inc., and Aegis Therapeutics, LLC.

Roger L. Hawley joins the founding team of Zogenix as Chief Executive Officer with over 19 years of distinguished commercial pharmaceutical experience, having most recently served as Executive Vice President, Commercial and Technical Operations for InterMune (NASDAQ:INTM) since 2003. Prior to joining InterMune, Mr. Hawley held senior executive level commercial roles with Prometheus Laboratories Inc., Elan Pharmaceuticals, Inc. (NYSE:ELN), and GlaxoSmithKline (NYSE:GSK), where he ended his fourteen-year career as Vice President of Sales - CNS/ GI Division in 2001. During his career, Mr. Hawley has had the unique opportunity to participate in the launch and commercialization of three of the currently marketed triptan migraine therapies as well as other CNS products. Currently he serves on the board of Targeted Genetics (NASDAQ:TGEN) and Alios Biopharma, Inc., a private biotechnology company.

Stephen J. Farr, Ph.D. brings over 20 years of drug delivery science and drug/device product development to his founding role of President and Chief Operating Officer. Dr. Farr most recently served as Senior Vice President and Chief Scientific Officer of Aradigm, Corp. (NASDAQ:ARDM), where he served as scientific director for Aradigm's inhaled insulin program, and was technical director of the Intraject(R) program. While at Aradigm, Dr. Farr played a key leadership role in developing Intraject(R) sumatriptan to its current advanced stage of technical development.

Mr. Garner, Mr. Hawley, and Dr. Farr are joined by founding team members Jonathan Rigby, Bret E. Megargel, and John J. Turanin. Mr. Rigby joins Zogenix with over 16 years of pharmaceutical experience, most recently serving as Vice President of Business Development for Aradigm, Corp., where he led the original acquisition and subsequent strategic development of Intraject(R). Mr. Rigby also serves as Vice Chair of the Association of Needle Free Injection Manufacturers.

Mr. Megargel has over 15 years of related healthcare experience, having most recently served as Vice President/General Manager for Planet Technologies, Inc., and Vice President, Business Development for Avera Pharmaceuticals, Inc.

Mr. Turanin adds over 20 years of pharmaceutical and medical device development experience, having most recently served as Vice President, Corporate Planning, and Program Management at Aradigm, Corp., where he led several product development programs, including Intraject(R) sumatriptan.

Zogenix, Inc.

Zogenix, Inc., with offices in Hayward and San Diego, CA, is a private, specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. The company's initial focus is the completion of the late-stage development and commercialization of Intraject(R) sumatriptan -- a needle-free, single-use, disposable, subcutaneous delivery system that will compete in the $2.5 billion triptan segment of the migraine market. Additional information on the company can be found at

Intraject is a registered trademark of Zogenix, Inc.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Aug 28, 2006
Previous Budgets $2M to Produce 75,000 Internet-Friendly How-to Videos in the Next Eighteen Months via Freelance Filmmakers.
Next Article:RCN Leaps into the Quadruple Play with Wireless Offering Powered by MobilePro.

Related Articles
Encouraging signs but no woodpecker. (Biology).
eVerge Group Names Former PeopleSoft Exec to Head Sales and Marketing Organization.
Rick Lowenstein Joins Deltek as Executive Vice President of Professional Services; Former Vice President of Agile Software Brings 20 Years of...
Zogenix, Inc. Raises $60 Million in Series A Venture Financing; Names Board of Directors.
Deltek Names Holly Kortright New Senior Vice President of Human Resources.
Zogenix Appoints J.D. Haldeman Vice President, Commercial Strategy & Corporate Communications.
Double Fusion Hires Recruiting and Organization Specialist Richard Willoughby as VP of Human Resources.
MonoSphere Appoints Gregg Westerbeck to Vice President of Sales.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters